NY-AB-INBEV
30.5.2024 07:01:28 CEST | Business Wire | Press release
Today, Danone has joined AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), The Coca-Cola Company, Colgate-Palmolive Company, and Unilever as the fifth partner in the 100+ Accelerator, the groundbreaking program dedicated to pioneering sustainable innovation across global supply chains.
Launched in 2018 by AB InBev, the 100+ Accelerator has rapidly become a cornerstone initiative for catalyzing environmental stewardship and sustainable business practices through global collaboration and groundbreaking solutions in critical areas such as water stewardship, circular economy, sustainable agriculture, and climate action. In 2021, the 100+ Accelerator welcomed its first three partners to expand this unique approach to innovation and to further establish the value proposition of the program’s brand and mission. To date, it has accelerated 148 companies in 38 countries.
“Sustainability is core to our business strategy and fulfills our purpose of dreaming big to create a future with more cheers,” said Ingrid De Ryck, Chief Sustainability Officer of AB InBev. “In the 5 years since its launch, the 100+ Accelerator has helped us identify and scale solutions to business challenges, advance our 2025 sustainability goals and improve resilience across supply chains. We welcome Danone as a strategic partner in the 100+ Accelerator and are excited to continue developing the program’s impact through industry collaboration.”
“Our combined global reach will undoubtedly propel the 100+ Accelerator to new heights, driving broader adoption of sustainable innovations that will benefit our planet, our communities and our future.” Vikram Agarwal, Chief Operations Officer, Danone, also expressed his enthusiasm for the partnership: "This collaboration with 100+ Accelerator is yet another milestone in Danone's sustainability journey and is a direct result of our Partner For Growth program. It shows our commitment to working with all partners across our ecosystem to leverage our respective strengths to create shared value. With 100+ Accelerator, start-ups will be able to harness our internal resources to scale-up innovation that will deliver tangible environmental benefits across the value chain.”
Isabelle Esser, Danone Chief Research, Innovation, Quality and Food Safety Officer added, “We are proud to join the 100+ Accelerator program, which is fully aligned with our ambition to drive sustainable innovation for the future of our planet and our consumers. At Danone, we believe that strong partnerships are essential to help us stay one step ahead of global challenges, while continuing to honor our mission of shaping the food of tomorrow.”
The program's effectiveness is evidenced by its impact:
- Implementation of a range of technologies that help improve water efficiency including nanotechnology, electrochemistry and spectroscopy.
- Enhanced traceability and support systems for smallholder farmers, endeavoring to improve livelihoods and agricultural sustainability across continents.
- Fleet optimization including EV retrofitting, hydrogen co-fueling, aerodynamic solutions and hybrid charging.
- New cooling applications including thermodynamic coatings and magnetic refrigeration.
- Bio-based, compostable packaging alternatives or additives from banana fiber, spent grain, corn husk, bacterial nano-cellulose among others.
Applications for the sixth cohort of the accelerator will open on May 30. Forward-thinking entrepreneurs are invited to apply at www.100accelerator.com.
With the collective capabilities of AB InBev, The Coca-Cola Company, Colgate-Palmolive, Danone, and Unilever, the 100+ Accelerator will continue to scale innovative solutions to create a more sustainable world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529855383/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom